BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37022767)

  • 1. A modelled evaluation of the impact of COVID-19 on breast, bowel, and cervical cancer screening programmes in Australia.
    Nickson C; Smith MA; Feletto E; Velentzis LS; Broun K; Deij S; Grogan P; Hall M; He E; St John DJ; Lew JB; Procopio P; Simms KT; Worthington J; Mann GB; Canfell K
    Elife; 2023 Apr; 12():. PubMed ID: 37022767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study.
    de Jonge L; Worthington J; van Wifferen F; Iragorri N; Peterse EFP; Lew JB; Greuter MJE; Smith HA; Feletto E; Yong JHE; Canfell K; Coupé VMH; Lansdorp-Vogelaar I;
    Lancet Gastroenterol Hepatol; 2021 Apr; 6(4):304-314. PubMed ID: 33548185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of COVID-19 on screening for colorectal, gastric, breast, and cervical cancer in Korea.
    Park H; Seo SH; Park JH; Yoo SH; Keam B; Shin A
    Epidemiol Health; 2022; 44():e2022053. PubMed ID: 35760396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A population-based survey of self-reported delays in breast, cervical, colorectal and lung cancer screening.
    Gunn CM; Berrian K; Weiss JE; Tosteson AAN; Hasson RM; Di Florio-Alexander R; Peacock JL; Rees JR
    Prev Med; 2023 Oct; 175():107649. PubMed ID: 37517458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
    Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A national quality improvement study identifying and addressing cancer screening deficits due to the COVID-19 pandemic.
    Joung RH; Nelson H; Mullett TW; Kurtzman SH; Shafir S; Harris JB; Yao KA; Brajcich BC; Bilimoria KY; Cance WG
    Cancer; 2022 Jun; 128(11):2119-2125. PubMed ID: 35307815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. History, development and future of cancer screening in Australia.
    Olver IN; Roder D
    Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating Screening Participation, Follow-up, and Outcomes for Breast, Cervical, and Colorectal Cancer in the PROSPR Consortium.
    Barlow WE; Beaber EF; Geller BM; Kamineni A; Zheng Y; Haas JS; Chao CR; Rutter CM; Zauber AG; Sprague BL; Halm EA; Weaver DL; Chubak J; Doria-Rose VP; Kobrin S; Onega T; Quinn VP; Schapira MM; Tosteson ANA; Corley DA; Skinner CS; Schnall MD; Armstrong K; Wheeler CM; Silverberg MJ; Balasubramanian BA; Doubeni CA; McLerran D; Tiro JA
    J Natl Cancer Inst; 2020 Mar; 112(3):238-246. PubMed ID: 31292633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent participation in breast, cervical, and colorectal cancer screening in the Netherlands.
    Kregting LM; Olthof EMG; Breekveldt ECH; Aitken CA; Heijnsdijk EAM; Toes-Zoutendijk E; de Koning HJ; van Ravesteyn NT
    Eur J Cancer; 2022 Nov; 175():180-186. PubMed ID: 36126478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Oncological organized screening programmes in the COVID-19 era: an Italian survey on accrued delays, reboot velocity, and diagnostic delay estimates].
    Mantellini P; Battisti F; Armaroli P; Giubilato P; Ventura L; Zorzi M; Battagello J; Sassoli de Bianchi P; Senore C; Zappa M
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):344-352. PubMed ID: 33412828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The diffusion of screening programmes in Italy, year 2010].
    Zappa M; Dardanoni G; Giorgi Rossi P; Grazzini G; Naldoni C; Paci E; Pirola ME; Pizzuti R; Segnan N; Zorzi M; Federici A
    Epidemiol Prev; 2012; 36(6 Suppl 1):3-7. PubMed ID: 23293267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of cancer screening restart strategies after COVID-19 disruption.
    Kregting LM; Kaljouw S; de Jonge L; Jansen EEL; Peterse EFP; Heijnsdijk EAM; van Ravesteyn NT; Lansdorp-Vogelaar I; de Kok IMCM
    Br J Cancer; 2021 Apr; 124(9):1516-1523. PubMed ID: 33723386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cancer screening programme in health care workers].
    Pisati G; Cerri S; Marinelli M; Tedeschi B; Valsecchi E
    G Ital Med Lav Ergon; 2011; 33(2 Suppl):57-60. PubMed ID: 22187927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. County-Level Social Vulnerability and Breast, Cervical, and Colorectal Cancer Screening Rates in the US, 2018.
    Bauer C; Zhang K; Xiao Q; Lu J; Hong YR; Suk R
    JAMA Netw Open; 2022 Sep; 5(9):e2233429. PubMed ID: 36166230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cancer screening programmes in Italy: unification element or factor for further division?].
    Zappa M; Federici A; Salmaso S
    Epidemiol Prev; 2011; 35(5-6 Suppl 2):100-2. PubMed ID: 22166878
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis.
    Smith MA; Burger EA; Castanon A; de Kok IMCM; Hanley SJB; Rebolj M; Hall MT; Jansen EEL; Killen J; O'Farrell X; Kim JJ; Canfell K
    Prev Med; 2021 Oct; 151():106623. PubMed ID: 34029578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient Navigation for Comprehensive Cancer Screening in High-Risk Patients Using a Population-Based Health Information Technology System: A Randomized Clinical Trial.
    Percac-Lima S; Ashburner JM; Zai AH; Chang Y; Oo SA; Guimaraes E; Atlas SJ
    JAMA Intern Med; 2016 Jul; 176(7):930-7. PubMed ID: 27273602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands.
    Dinmohamed AG; Cellamare M; Visser O; de Munck L; Elferink MAG; Westenend PJ; Wesseling J; Broeders MJM; Kuipers EJ; Merkx MAW; Nagtegaal ID; Siesling S
    J Hematol Oncol; 2020 Nov; 13(1):147. PubMed ID: 33148289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in Screening Abnormality Rates and Follow-Up of Breast, Cervical and Colorectal Cancer Screening within the PROSPR Consortium.
    Tosteson AN; Beaber EF; Tiro J; Kim J; McCarthy AM; Quinn VP; Doria-Rose VP; Wheeler CM; Barlow WE; Bronson M; Garcia M; Corley DA; Haas JS; Halm EA; Kamineni A; Rutter CM; Tosteson TD; Trentham-Dietz A; Weaver DL;
    J Gen Intern Med; 2016 Apr; 31(4):372-9. PubMed ID: 26658934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.